Analystreport

Seres Therapeutics (MCRB) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $22.00 price target on the stock.

Seres Therapeutics, Inc.  (MCRB) 
Last seres therapeutics, inc. earnings: 11/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.serestherapeutics.com